Managing Partner and co-founder, Columbus Venture Partners
Damià Tormo has spent the last 20 years working in the biotech industry and has founded several biotech companies including Highlight Therapeutics, Artax Biopharma, Viralgen (adquired by Bayer), Vivet Therapeutics (option by Pfizer), PTS (Adquired by Arcline), Tyris Therapeutics, Recovid (adquired by Vitro) or Radioterapia de Protones.
Damia is currently Director of Artax, Highlight, Tyris, Algenex, Aleta, Integra and Syngoi. He has also served on the Boards of Sanifit (adquired by Vifor), Recovid, Viralgen and PTS.
Moreover, Damia is the President of Fundación Columbus, a non-profit organization that develops advanced therapies for children with cancer and ultra-rare genetic diseases.
He holds a PhD in in Immunology and Molecular Genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn and has been researcher at Uniklinik Bonn, University of Michigan or the Spanish National Cancer Center (CNIO)